Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
adenosine phosphorylation
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "adenosine phosphorylation" in MCE Product Catalog:
15
15 Publications Verification
Synonyms: Vengicide
Category:
Infection Antibiotics Microorganism Disease Research Antibacterial Disease Research Fields Other Antibiotics
Target:
8
2
2 Cited Publications
Synonyms: GDP disodium salt
Cat. No.: HY-N7368
CAS No.: 55366-56-8
Category:
Flavonols Plant Flavonoids Neurological Disease Phenols Polyphenols Other Families Extract Disease Research Fields Inflammation/Immunology
Target:
Cat. No.: HY-103322
CAS No.: 1135306-29-4
Target:
Research Areas:
6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration .
Inosine dose-dependently induces hA2AR-mediated ERK1/2 phosphorylation .
Inosine (100 μM; 24 hours) reduces oxidative stress in MES 23.5 cells cultured with astrocytes .
In Vivo:Inosine (10-100 mg/kg; i.p.) exhibits antinociceptive effect in mice .
Cat. No.: HY-116005
CAS No.: 483341-15-7
Target:
Research Areas:
A-286501 is an orally active adenosine kinase inhibitor with an IC50 of 0.47 nM (rat brain cytosol). A-286501 blocks the phosphorylation of adenosine to AMP and increases adenosine. A-286501 mediates non-opioid adenosine receptor-dependent antinociceptive and anti-inflammatory effects, reduces paw edema, myeloperoxidase activity, and tactile allodynia, and produces antinociceptive effects in acute, inflammatory, neuropathic, and hyperalgesic models. A-286501 can be used in research on inflammatory pain, neuropathic pain, and diabetic neuropathy .
Cat. No.: HY-114901
CAS No.: 186141-75-3
Target:
Research Areas:
A-134974 is a selective adenosine kinase (ADK) inhibitor, with an IC50 of 0.06 nM and 45 nM in rat brain cytoplasmic ADK enzyme assays and intact IMR-32 cells, respectively . A-134974 inhibits adenosine phosphorylation and elevates intracellular and extracellular adenosine levels, alleviates neuropathic tactile allodynia and inflammatory thermal hyperalgesia via endogenous adenosine signaling in the spinal cord, and shows favorable dose separation between its analgesic effects and motor function impairment . A-134974 can be used in research on neuropathic pain, inflammatory pain, RNA silencing and thermoregulation .
Cat. No.: HY-W250160
CAS No.: 100403-24-5
Synonyms: Polydeoxyribonucleotide
Category:
Cat. No.: HY-100126R
CAS No.: 69-33-0
Synonyms: 7-Deazaadenosine (Standard)
Cat. No.: HY-170948
CAS No.: 3007566-23-3
Target:
Research Areas:
A2AR modulator-1 (Compound 45) is a selective negative allosteric adenosine A2a receptor (A2aR) modulator with an IC50 value of 9 nM. A2AR modulator-1 reduces the affinity of endogenous adenosine for the receptor and inhibits cAMP signaling pathway activation. A2AR modulator-1 potently restores pCREB phosphorylation in CD4 + T cells, reversing immunosuppression in the tumor microenvironment, and shows potential to suppress tumor growth and metastasis in triple-negative breast cancer models .
Cat. No.: HY-163978
CAS No.: 1350113-04-0
Target:
Research Areas:
YGZ-331 is a sedative with a calming effect. YGZ-331 is a derivative of the adenosine nucleoside NGBA, which can increase GABA levels. YGZ-331 exerts a sedative-hypnotic effect by activating A1R and A2aR, and inhibiting CaMKII phosphorylation (pCaMKII) levels. YGZ-331 can reduce the spontaneous motor activity of mice .
Cat. No.: HY-103248R
CAS No.: 606-58-6
Synonyms: Vengicide (Standard)
Target:
Cat. No.: HY-137381
CAS No.: 30275-80-0
Synonyms: N6-Benzoyl-cAMP
Target:
Research Areas:
6-Bnz-cAMP, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP does not activate the Epac signaling pathway. 6-Bnz-cAMP inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. 6-Bnz-cAMP can be used in studies related to bone tissue repair and regeneration .
Cat. No.: HY-N7368R
CAS No.: 55366-56-8
Cat. No.: HY-183599
CAS No.: 2433765-51-4
Target:
Research Areas:
MK-1088 is an orally active A2A/A2B adenosine receptor antagonist with human A2A Ki of 0.31 nM, human A2B Ki 5.3 nM. MK-1088 blocks receptor downstream signaling, inhibits CREB phosphorylation and reverses adenosine-mediated immunosuppression. MK-1088 restores TNF−α release and enhances tumor immune surveillance. MK-1088 can be used for the research of cancer[1].
Cat. No.: HY-180575
CAS No.: 2210298-14-7
Research Areas:
LCB-2122 is an adenosine-like nucleoside analogue bearing a C2'-stereogenic all-carbon quaternary center. LCB-2122 can prevent Doxorubicin (HY-15142A)-induced cardiomyocytes apoptosis with an IC50 of 0.5 μM and prevent Imatinib (HY-15463)-induced apoptosis. LCB-2122 can activate AMPK signaling and induce the phosphorylation of AMPK and its downstream substrate, acetyl-CoA carboxylase (ACC). LCB-2122 can reduce Doxorubicin-induced mitochondrial damage. LCB-2122 can be used for the research of heart failure .
Cat. No.: HY-129272
CAS No.: 63768-47-8
Research Areas:
MY-1250 is a histamine release inhibitor. MY-1250 is the major active metabolite of Repirinast (HY-109544). MY-1250 stimulates adenylate cyclase to increase intracellular cyclic adenosine monophosphate levels, reduce intracellular ATP levels, inhibit antigen-induced intracellular calcium store mobilization, and induce phosphorylation of the 78 kDa protein. MY-1250 inhibits antigen- and phospholipase A2-induced release of histamine and slow-reacting substance of anaphylaxis from mast cells, lung tissue fragments and basophils. MY-1250 can be used in research related to allergic diseases and bronchial asthma .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
